USE OF LIRAGLUTIDE AFTER KIDNEY TRANSPLANTATION IN PATIENT wITH vIRAL HEPATITIs C

Abstract

The paper reviews the case from practical experience with estimation of effi-ciency and safety of liraglutide (victose) in patient after kidney transplantation with diabetes mellitus type II and chronic viral hepatitis C administered immune-suppressive therapy (Prograf, Myfortic, and Prednisolone). During the first visit, against the insulin therapy the doctors have managed to compensate diabetes and normalise transaminases. The episodes of hy-poglycaemia and excessive weight remained. Liraglutide allowed decreasing the glycated haemoglobin con-tent by 19 %, removing the episodes of hypoglycaemia, and regulating the body mass index. The 9-month case follow-up did not reveal increasing levels of transaminases and creatinine. The content of Prograf in blood serum remained stable.